BGNE241220C175000
- 4.85
- 0.000.00%
BeiGene Newsroom
Sector Update: Health Care Stocks Steady Premarket Friday
Sector Update: Health Care
CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland
Express News | JPMorgan Chase & Co's Long Position in Shares of Beigene Increases to 10.94% on Dec 9 From 9.92% - HKEX
US MOVERS&SHAKERS Dec 09-Dec 13, 2024
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
CSPC PHARMA and BEIGENE have entered into an exclusive licensing agreement for SYH2039.
CSPC PHARMA (01093) announced that the group has entered into an exclusive licensing agreement with BeiGene Switzerland GmbH (BEIGENE) for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as for any Pharmaceuticals composed of or containing this compound for development, manufacturing, and commercialization on a Global scale. Under the agreement, and in accordance with its terms and conditions, the group agrees to grant BEIGENE exclusive rights for the Global development, manufacturing, and commercialization of that compound and product. The group will receive a total of 1.50.
CSPC Pharmaceutical Partners With BeiGene on Innovative Cancer Drug
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
Express News | Beigene Announces Global Licensing Agreement for Mat2a Inhibitor
CSPC PHARMA (01093.HK) has entered into an exclusive licensing agreement with BEIGENE for SYH2039.
On December 13, Glori has announced that CSPC PHARMA (01093.HK) has entered into an exclusive licensing agreement with BeiGene Switzerland GmbH ("BEIGENE") regarding the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as any Pharmaceutical that consists of or contains this compound for Global development, manufacturing, and commercialization. Under the terms and conditions of this agreement, the group agrees to grant BEIGENE exclusive rights to develop, manufacture, and commercialize this compound and this product globally.
Express News | CSPC Pharmaceutical - Exclusive License Agreement for Syh2039 With Beigene
Beigene Insider Sold Shares Worth $7,805,106, According to a Recent SEC Filing
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $286
China to Lift Fiscal Spending to Boost Economy
JMP Securities Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $288
BeiGene's Strong Pipeline and Financial Position Make It a Compelling Buy Opportunity
BeiGene Secures $400 Million Facility From China Merchants Bank
China Central Economic Work Conference: A Key Indicator for Future Market Trends
Insider Sale: Director at $BGNE (BGNE) Sells 916,964 Shares